HRMY

Harmony Biosciences Holdings, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24

Figures on this page computed 2026-11-08 12:32 UTC

Last close

34.42USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-24

12.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
53.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
18.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
40.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
0.19Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.98x

3.02x

3.06x

0.87x

0.94x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales1.98x
Its own average over 7 years, 439.2M.
Profit3.02x
Its own average over 8 years, 52.5M.
Free cash flow3.06x
Its own average over 8 years, 113.7M.
Debt0.87x
Its own average over 8 years, 194.1M.
Price0.94x
Its own average over 7 years, 37. Market data, 2026-11-04

Free cash flow is furthest from its own average, at 3.06 times.

Sales is 1.98 times its own 7-year average; Profit is 3.02 times its own 8-year average; Free cash flow is 3.06 times its own 8-year average; Debt is 0.87 times its own 8-year average; Price is 0.94 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales against its own 7-year average1.98
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
Profit against its own 8-year average3.02
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
Free cash flow against its own 8-year average3.06
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
Debt against its own 8-year average0.87
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
Price against its own 7-year average0.94Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD